Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases
22.5.2026 07:00:00 CEST | Business Wire | Press Release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil.
Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region.
“Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well-positioned to bring this important therapy to patients living with autoimmune diseases. Together, we aim to improve access to effective and affordable treatment options across the region.”
"Our collaboration with Polpharma Biologics marks a significant milestone for Tuteur," said Jonathan Hahn, President of Tuteur. "Partnering with an organization of their caliber reinforces our commitment to expanding access to world-class biologics for patients throughout Latin America."
The biosimilar, currently in development, is designed to provide an effective and well-tolerated treatment option for patients with autoimmune conditions. Regulatory submission is anticipated within the next three years.
About Polpharma Biologics
Polpharma Biologics is a group of biopharmaceutical companies focused on the development and manufacturing of biopharmaceuticals and biosimilars for global markets. Its Switzerland-based biosimilars platform manages the entire value chain—from product selection and investment allocation through development and commercialization—ensuring efficient progression from concept to launch in close collaboration with global partners. The company’s biosimilar portfolio spans multiple programs at various stages of development, from early-stage research to commercialization. Its international team brings deep expertise across program leadership, regulatory strategy, CMC integration, device development, clinical oversight, and quality assurance. Through Polpharma Biologics partnerships with trusted CDMOs, Polpharma Biologics delivers end-to-end biosimilar solutions, from cell line development to finished products, across key therapeutic areas. Polpharma Biologics is committed to accelerating access to biologic therapies worldwide by maintaining a robust and expanding pipeline of biosimilars.
More information: https://polpharmabiologics.com/polpharma-biologics-and-tuteur/
About Tuteur
Tuteur is a leading company in specialized medicine across Latin America, delivering innovative therapies and solutions that address complex medical needs. With a strong commitment to patient outcomes, operational excellence, and strategic partnerships, Tuteur combines deep expertise in manufacturing and distribution of specialty medicines to serve healthcare providers and patients across the region. Driven by a robust pipeline of specialized treatments and a patient-centric approach, Tuteur continues to expand its presence in LATAM while maintaining a focus on innovation, efficiency, and sustainable growth.
More information: https://tuteurgroup.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260521106271/en/
Contacts
Media contact:
Natalia Kwiecień
natalia.kwiecien@polpharmabiologics.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press Release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press Release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Global Stars Ahn Hyo-seop and Khalid Release New Cross-Market Single “Something Special” via FANDOM Today22.5.2026 06:00:00 CEST | Press Release
Today marks the official release of “Something Special,” the highly anticipated cross-market collaboration from international star Ahn Hyo-seop and multi-platinum recording artist Khalid, available now via FANDOM on all major streaming platforms. Stream the single HERE. Musicow will also release an official music video in June, highlighting the unique chemistry between Ahn Hyo-seop and Khalid while bringing the song’s cross-cultural collaboration to life on screen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522928365/en/ Ahn Hyo-seop, globally recognized for his breakout role as “Jinu,” the leader of demon boy band Saja Boys in Netflix’s animated phenomenon KPop Demon Hunters, joins forces with Grammy-nominated artist Khalid for a genre-blending release that bridges the worlds of K-pop and U.S. R&B - two of the most influential forces shaping contemporary global music culture. Produced by Woo “RAINSTONE” Rhee, known f
Lenovo Group: Q4 and Full Year Financial Results 2025/2622.5.2026 01:47:00 CEST | Press Release
Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported fourth quarter and full year results for fiscal year 2025/26, marking an exceptional Q4 and the strongest year in the Group’s history. During the quarter, overall Group revenue reached an all-time fourth quarter high of US$21.6 billion, up 27% year-on-year, marking the highest year-on-year growth rate in five years, with adjusted net income[1]doubling year-on-year to US$559 million. AI-related revenue[2] stood out as a leading growth engine, growing 84% year-on-year to account for 38% of total Group revenue in Q4. For the full year, the Group delivered record revenue of US$83.1 billion, with adjusted net income growing 42% year-on-year to US$2 billion. All business groups achieved solid double-digit year-on-year revenue growth, with a notable record full-year performance from the Infrastructure Solutions Group (ISG) with revenue of US$19.2 billion, full-year profitability, and US$
The Estée Lauder Companies & Puig End Discussions Regarding a Potential Business Combination21.5.2026 22:05:00 CEST | Press Release
On March 23, 2026, The Estée Lauder Companies Inc. (NYSE: EL) and Puig confirmed they were in discussions regarding a potential business combination, but unless and until an agreement was signed between the companies, there could be no assurances regarding the deal or its terms. The Estée Lauder Companies and Puig today announced that the parties have terminated discussions regarding a potential business combination. The Estée Lauder Companies remains fully focused on continuing to execute its Beauty Reimagined strategy, which is well underway and delivering positive results. “We are grateful for the conversations we have had with Puig,” said Stéphane de La Faverie, President and Chief Executive Officer of The Estée Lauder Companies. “Today, we are reiterating our confidence in the power of our incredible brands, our talented teams, and our strength as a standalone company. We are more optimistic than ever about our ability to unlock significant long-term value through Beauty Reimagine
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom